Mark E. Kaufmann
Directeur Général chez The Linguist Institute, Inc.
Profil
Mark E.
Kaufmann is the founder of The Linguist Institute, Inc. founded in 2007, where he is currently the Chief Executive Officer.
He was the President & Chief Executive Officer of CelMed BioSciences, Inc. and Allostera Pharma, Inc. from 2008 to 2013.
He also held positions as Director-Planning & Analysis at MedImmune LLC, Vice President-Corporate Development at Nexia Biotechnologies, Inc., and Chief Financial Officer at Conceptis Technologies, Inc. He was the CFO, Treasurer & Principal Accounting Officer at Ardelyx, Inc. from 2017 to 2020.
Mr. Kaufmann received his undergraduate degree from Harvard University and his MBA from Stephen M.
Ross School of Business.
Postes actifs de Mark E. Kaufmann
| Sociétés | Poste | Début |
|---|---|---|
The Linguist Institute, Inc.
 The Linguist Institute, Inc. Internet Software/ServicesTechnology Services The Linguist Institute, Inc. operates web and mobile language learning platform. It provides e-learning services. The company was founded by Mark E. Kaufmann and Steven M. Kaufman in 2007 and is headquartered in West Vancouver, Canada. | Directeur Général | 01/01/2007 |
Anciens postes connus de Mark E. Kaufmann
| Sociétés | Poste | Fin |
|---|---|---|
| ARDELYX, INC. | Directeur Financier/CFO | 12/03/2020 |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Directeur Général | 09/09/2013 |
CelMed BioSciences, Inc.
 CelMed BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada. | President | 28/11/2006 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Conceptis Technologies, Inc.
 Conceptis Technologies, Inc. Internet Software/ServicesTechnology Services Part of WebMD Health Corp., Conceptis Technologies, Inc. is a Canadian company that provides online and offline medical education and promotion aimed at physicians. The company is based in Montréal, Canada. Conceptis Technologies was acquired by Emdeon Corp. on December 02, 2005 for $19.86 million. | Directeur Financier/CFO | - |
Formation de Mark E. Kaufmann
| Harvard University | Undergraduate Degree |
| Stephen M. Ross School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARDELYX, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
CelMed BioSciences, Inc.
CelMed BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Nexia Biotechnologies, Inc.
 Nexia Biotechnologies, Inc. BiotechnologyHealth Technology Nexia Biotechnologies produces therapeutic proteins and other biomaterials for the treatment of serious disease | Health Technology |
Conceptis Technologies, Inc.
Conceptis Technologies, Inc. Internet Software/ServicesTechnology Services Part of WebMD Health Corp., Conceptis Technologies, Inc. is a Canadian company that provides online and offline medical education and promotion aimed at physicians. The company is based in Montréal, Canada. Conceptis Technologies was acquired by Emdeon Corp. on December 02, 2005 for $19.86 million. | Technology Services |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
The Linguist Institute, Inc.
The Linguist Institute, Inc. Internet Software/ServicesTechnology Services The Linguist Institute, Inc. operates web and mobile language learning platform. It provides e-learning services. The company was founded by Mark E. Kaufmann and Steven M. Kaufman in 2007 and is headquartered in West Vancouver, Canada. | Technology Services |
